TrialGynecologic oncology2013

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

R J Schilder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.